Strangvac, a vaccine against equine strangles released for sales in the UK
Stockholm, July 20th, 2022 - Intervacc AB (publ) announces today that the first batch of Strangvac for sale in the UK has been released.
“The first batch of Strangvac for the UK market has now been released. This means that sales of Strangvac in the UK can begin shortly”, explains Andreas Johansson, Logistics Manager at Intervacc.
"Strangvac is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden and Denmark. The UK is expected to be one of the largest markets in Europe for vaccines against the highly contagious infectious disease equine strangles. With the release, we have a finished product approved for launch in the UK. This is significant milestone for our launch in Europe.” comments Andreas Andersson, CEO of Intervacc.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on July 20, 2022.
About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10
